RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) against seasonal influenza with the goal of providing immediate, powerful and long-lasting protection against the risk of severe viral disease.
Engineered Immunity For the People Vaccines Miss
Why now
Influenza continues to pose a global threat, with seasonal evolution undermining vaccine effectiveness. The greatest impact falls on immunocompromised groups—newborns, the elderly, and patients with weakened immunity due to chronic conditions or treatments. Our focus is on providing the missing protection from infection, that does not depend on the person being able to respond maximally to seasonal vaccines.
